treatment | Page 14 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

treatment

Anurag Singh, MD

Singh, Anurag
Associate Professor, Hematologic Malignancies and Cellular Therapeutics
The University of Kansas

Dr. Singh completed his Internal Medicine Residency as well as his Hematology and Oncology Fellowship at the State University of New York Upstate Medical University. His clinical interests include mismatched donor stem cell transplantation , Hereditary predisposition to hematologic malignancies and Cellular therapies. His research interests include donor selection in stem cell transplantation, Transplantation for myeloid malignancies , GVHD prophylaxis and germline predisposition to Hematological malignancies

Cell-autonomous dysregulation of interferon signaling drives clonal expansion of SRSF2-mutant MDS stem/progenitor cells

Key Points
SRSF2 mutations blunt responsiveness of MDS cells to IFN stimulation and promote their clonal fitness by downregulating STAT1 expression

Proteasome inhibition restores STAT1 protein level and sensitivity of SRSF2-mutant MDS cells to IFN, suggesting a new therapeutic strategy

2025 Boston Patient and Family Conference

Event Date: 
Sat, 09/27/2025 - 7:30am (EDT)
Conference Event Type: